GSK Exits Respiratory Partner Innoviva In $392M Deal

  • GlaxoSmithKline plc GSK has agreed to sell 32 million shares in Innoviva Inc INVA back to the royalty management company, raising $392 million, at a 3% discount or $12.25 per share.
  • Innoviva, a royalty management company that collaborates with GSK on respiratory treatments, including Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta, has counted GSK among its investors for years.
  • Now, GSK is selling its holdings, with plans to use proceeds to “make further investment behind the group’s strategic priorities.”
  • “This equity disposal releases capital to enable GSK to make further investment behind the group’s strategic priorities,” said GSK.
  • Following the settlement of the transaction, GSK will no longer hold any Innoviva stock.
  • Price Action: INVA shares are up 7.12% at $13.17, while GSK shares are down 0.36% at 39.11 during the market session on the last check Thursday.
Loading...
Loading...
GSK Logo
GSKGSK PLC
$41.260.15%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
73.62
Growth
78.17
Quality
15.09
Value
28.38
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...